ImageneBio, Inc. Market Cap ($46.52 Million)
Market Cap & Net Worth: ImageneBio, Inc. (IMA)
ImageneBio, Inc. market cap. ImageneBio, Inc. (NASDAQ:IMA) has a market capitalization of $46.52 Million ($46.52 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21994 globally and #4902 in its home market, demonstrating a -3.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ImageneBio, Inc.'s stock price $4.09 by its total outstanding shares 11374130 (11.37 Million). Also see ImageneBio, Inc. cash conversion from operations for how efficiently the company converts equity into cash flow.
ImageneBio, Inc. Market Cap History (2025–2026)
ImageneBio, Inc. market cap history from 2025 to 2026. Data shows growth from $78.48 Million to $46.52 Million (0.00% CAGR). Check ImageneBio, Inc. (IMA) stock price for real-time trading data and today's change.
ImageneBio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ImageneBio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IMA year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
98.10x
ImageneBio, Inc.'s market cap is 98.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $78.48 Million | $800.00K | -$45.35 Million | 98.10x | N/A |
Competitor Companies of IMA by Market Capitalization
Companies near ImageneBio, Inc. in the global market cap rankings as of November 3, 2026. Also see balance sheet size of ImageneBio, Inc. for a full breakdown of the balance sheet.
Key companies related to ImageneBio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ImageneBio, Inc. (2025–2026)
Market capitalization of ImageneBio, Inc. from 2025 to today. Between 2025 and today, ImageneBio, Inc.'s market cap moved from $78.48 Million to $ 46.52 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $46.52 Million | -40.72% |
| 2025 | $78.48 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ImageneBio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.52 Million USD |
| MoneyControl | $46.52 Million USD |
| MarketWatch | $46.52 Million USD |
| marketcap.company | $46.52 Million USD |
| Reuters | $46.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more